ByTrending Posts
Is Short-Term Cost Control Undermining Long-Term Innovation? Novartis…
23 January 2026 Executive Summary Novartis has issued a call for structural reform in global healthcare policy, warning…
Is Regional Distribution Becoming a Strategic Lever for…
23 January 2026 Executive Summary Novartis Pharma Services AG has entered into a strategic distribution agreement with Vivian…
Can Localized Manufacturing Shield Big Pharma from Trade…
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation strategy, stating that…
Is U.S. Manufacturing the Next Growth Hedge for…
23 January 2026 Executive Summary Novartis has unveiled a $23 billion investment plan to significantly expand its U.S.…
Can Ianalumab Anchor Novartis’ Next Growth Cycle as…
23 Jan 2026 Executive Summary Novartis has secured Breakthrough Therapy designation for ianalumab, a late-stage immunology asset, reinforcing…
Can AI Become the Backbone of Global Health…
Executive Summary The Bill & Melinda Gates Foundation and OpenAI have announced a $50 million public–private initiative, Horizon1000,…
Is AI Becoming Big Pharma’s Frontline Tool for…
Executive Summary Bristol Myers Squibb (BMS) has entered a strategic partnership with Microsoft to advance AI-driven early detection…
Is JPM 2026 the Moment Biopharma Finally Reset…
January 2026 — San Francisco | Global — The 44th Annual J.P. Morgan Healthcare Conference (JPM 2026) marked…
How Might Trump’s Strategic Healthcare Proposal Impact Innovation…
January 22, 2026 — Global — BioNexAI Market Insights reports that U.S. President Donald J. Trump has introduced…
Trending Posts
Latest Stories
Why Is Roche Returning to China for Its Next Antibody-Drug Conjugate Bet?
January 2026 – Strategic Partnerships | China Biopharma | Oncology & ADCs Roche has extended…
Roche Signals Dual Growth Strategy: Price Reform Alignment in the U.S. and Aggressive Expansion Across Oncology and Obesity
January 2026 | Pharma & Policy | Bloomberg Interview Insight Roche is positioning itself for…
Can Amgen’s Strategic Partnerships Redefine Access and Growth in the GLP‑1 Market?
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and…
Could Amgen’s 340B Pricing Practices Face Legal and Market Scrutiny?
23 January 2026 Executive Summary A healthcare advocacy group, Sagebrush, has filed a lawsuit against…
Gallery
